

ForPatients

by Roche

Juvenile Idiopathic Arthritis

A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)

Trial Status
Completed

Trial Runs In
12 Countries

Trial Identifier
NCT01904279 2012-003486-18
WA28117

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This open-label, multicenter study evaluated the pharmacokinetics, pharmacodynamics and safety of SC administered TCZ in participants with pJIA.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT01904279 2012-003486-18 WA28117
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=1 Year & <= 17 Years

Healthy Volunteers
No
